Junping Wang

Junping Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
ZWZhengyu Wu
Zhengyu Wu
PZPeng Zhou
Peng Zhou
YZYanan Zhao
Yanan Zhao
JWJunping Wang
Junping Wang
SGShan Gao
Shan Gao
Original Article Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis Zhengyu Wu, Peng Zhou, Yanan Zhao, Junping Wang, Shan Gao

25 February 2025 in Anti-Cancer Drugs
Verified
Journal Article
Open access
TTTingfei Tan
Tingfei Tan
SYSiyu Yuan
Siyu Yuan
WCWeiwei Chu
Weiwei Chu
JJJiemei Jiang
Jiemei Jiang
MCMeiling Chen
Meiling Chen
JWJunping Wang
Junping Wang
The combination of anlotinib with immune checkpoint inhibitors (ICIs) has become a common treatment modality in clinical practice. However, the optimal dose of anlotinib to use remains unclear. We collected patients with advanced non-small cell lung cancer (NSCLC) who received programmed cell death-1 blockade combined with different dose of anlotinib as second-line or later line therapy. Subsequently, the efficacy and safety of the combination therapy as well as subgroup analyses of different doses of anlotinib were analyzed. Cox regression was performed to analyze significant factors correlated with progression-free survival (PFS) and overall survival (OS). A total of 50 eligible patients with NSCLC who received anlotinib combined with ICIs therapy were included, of which 27 received low-dose anlotinib (8 mg), and 23 were administered high-dose anlotinib (12 mg). The median PFS (mPFS) and the median OS (mOS) for all patients were 8.3 months [95% confidence interval (CI): 6.3–10.3] and 17.6 months (95% CI: 16.5–18.7), respectively. Subgroup analyses showed that patients treated with 8 mg of anlotinib plus ICIs had significantly longer mPFS than those treated with 12 mg of anlotinib plus ICIs (8.7 vs 6.7 months, P = 0.016). The overall incidence of adverse events was 68.0%, and the most common adverse events of all grades were hypertension. Meanwhile, the incidence of adverse events was higher for 12 mg of anlotinib plus ICIs than that of 8 mg of anlotinib plus ICIs (82.6 vs 55.6%, P = 0.041). Low-dose anlotinib in combination with ICIs for advanced NSCLC may be an effective and well-tolerated option.

11 October 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
WCWen Cao
Wen Cao
GHGuangyao Huang
Guangyao Huang
YFYue Fang
Yue Fang
JSJingyuan Shao
Jingyuan Shao
SHSensen Hao
Sensen Hao
Hongzhi WangHongzhi Wang
Hongzhi Wang

11 February 2026 in Biomedical Chromatography
Verified
Journal Article
Open access
YYYuan Yao
Yuan Yao
GHGuang‐Yao Huang
Guang‐Yao Huang
TWTing‐Ting Wu
Ting‐Ting Wu
TTTing‐Fei Tan
Ting‐Fei Tan
FHFeng‐Mei Hu
Feng‐Mei Hu
JWJunping Wang
Junping Wang
Monoclonal antibody (mAb) therapies have revolutionized cancer treatment, significantly improving patient outcomes. However, the pharmacokinetics (PK) and pharmacodynamics (PD) of mAbs exhibit considerable variability due to nonlinear kinetics and individual differences, highlighting the need for therapeutic drug monitoring (TDM). Therefore, this study aimed to develop and validate a reliable LC–MS/MS method for the simultaneous quantification of bevacizumab, trastuzumab, rituximab, and pertuzumab in human serum and evaluate its clinical applicability. Characteristic peptides were identified using Skyline. Serum samples underwent Protein G purification and trypsin digestion. Separation used a C18 column with 0.1% FA and acetonitrile, and detection employed multiple reaction monitoring with cadonilimab as the internal standard. The method demonstrated excellent linearity (1–200 μg/mL), precision (CV < 8.9%), and accuracy (±9.8%). With a runtime of 12 min, the validated method requires only 10 μL of serum per sample and meets international validation standards, supporting the clinical monitoring of these therapies. A robust, cost‐effective, and high‐throughput LC–MS/MS method was successfully developed for the simultaneous quantification of four therapeutic mAbs. The method significantly reduces sample volume and analysis time while maintaining high accuracy and reproducibility, making it well‐suited for routine TDM and broader clinical applications.

11 September 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YYYuan Yao
Yuan Yao
SGShan Gao
Shan Gao
JWJunping Wang
Junping Wang
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have transformed the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). However, the inevitable emergence of acquired resistance significantly limits their long-term efficacy. While conventional accounts of resistance have primarily focused on tumor-intrinsic genetic alterations, accumulating evidence highlights the pivotal role of the tumor microenvironment (TME) in mediating therapeutic failure. The TME contributes to EGFR-TKI resistance through multiple interconnected mechanisms, including immunosuppression, extracellular matrix-mediated physical barriers, metabolic reprogramming, and compensatory signaling activation. These complex interactions create a protective niche that enables tumor cells to persist despite EGFR inhibition. Traditional Chinese medicine (TCM), characterized by its multi-component and multi-target properties, offers a potential systems-level approach to modulating the TME. Preclinical studies suggest that TCM-derived interventions may influence immune-cell polarization, stromal and vascular features, and tumor metabolism, thereby affecting EGFR-TKI sensitivity. This review focuses on TME-mediated EGFR-TKI resistance in NSCLC and appraises TCM interventions according to evidence type and directness. We evaluate current preclinical and clinical evidence, identify major limitations, and propose priorities for translational research. The review provides a conceptual framework for evaluating TCM-based combination strategies intended to attenuate EGFR-TKI resistance.

24 August 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
GHGuangyao Huang
Guangyao Huang
YWYing Wang
Ying Wang
YFYue Fang
Yue Fang
JSJingyuan Shao
Jingyuan Shao
SHSensen Hao
Sensen Hao
Hongzhi WangHongzhi Wang
Hongzhi Wang
Quantitative surface‐enhanced Raman spectroscopy (SERS) has long been impeded by stochastic hotspot formation, signal instability, and limited chemical fidelity in complex environments. Overcoming these intrinsic limitations requires structural control at the nanoscale rather than incremental improvements in signal amplification. Here, we introduce a mesoporous‐shell monolayer plasmonic architecture that enables quantitative and decision‐guided SERS by integrating deterministic hotspot geometry with regulated molecular accessibility and chemical stabilization of photosensitive analytes. This architecture produces predictable and reproducible SERS responses, shifting SERS from stochastic enhancement toward quantitative sensing. Using chemotherapeutic drugs as representative small‐molecule targets, the platform demonstrates ultrasensitive, multiplexed, and reproducible detection in standard solutions and complex biological matrices. Machine learning–assisted spectral analysis further enables accurate concentration prediction in patient blood samples in close agreement with liquid chromatography–mass spectrometry. Importantly, SERS‐guided dose adjustment in an orthotopic breast cancer mouse model maintains therapeutic efficacy while significantly reducing systemic toxicity, establishing a direct link between plasmonic sensing and decision‐guided intervention. This work defines a materials‐based framework for quantitative and decision‐enabled SERS, in which mesoporous‐shell monolayer architectures transform plasmonic nanostructures into functional platforms for real‐world molecular quantification and feedback‐controlled biomedical applications.